Table 3.
Characteristics of patients with FCHL included in the longitudinal study before and after treatment for their dyslipidemia
| Off- treatment | With treatment | P | |
|---|---|---|---|
| 25(OH)D (nmol/L) |
51.0 ± 31.3 |
58.9 ± 24.6 |
0.022 |
| BMI (Kg/m2) |
26.6 ± 2.6 |
26.6 ±2.6 |
0.778 |
| Waist (cm) |
92.7 ± 9.2 |
93.1 ± 8.8 |
0.518 |
| HOMA |
2.0 ± 1.1 |
2.2 ± 1.4 |
0.535 |
| Total cholesterol (mmol/L) |
7.4 (5.1-16.1) |
5.1 (3.8-8.9) |
0.000 |
| Triglycerides (mmol/L) |
2.8 (1.2-10.7) |
1.9 (0.8-3.8) |
0.000 |
| LDL-c (mmol/L) |
4.3 (1.4-7.8) |
3.0 (2.0-5.8) |
0.007 |
| HDL-c (mmol/L) |
1.2 ± 0.4 |
1.3 ± 0.3 |
0.000 |
| VLDL-c (mmol/L) |
1.3 (0.6-8.6) |
0.9 (0.4-3.3) |
0.000 |
| NEFA (mmol/L) |
0.6 (0.3-1.6) |
0.6 (0.3-1.4) |
0.313 |
| ApoB (g/L) |
1.4 ± 0.3 |
1.0 ± 0.2 |
0.000 |
| LDLsize (nm) |
25.3 (23.2-26.2) |
25.7 (24.8-26.5) |
0.058 |
| CRP (mg/L) | 2.0 (0.1-21.1) | 1.3 (0.3-12.2) | 0.823 |
P values according to paired T-test and Wilcoxon test.
FCHL: Familial combined hyperlipidemia, 25(OH)D: 25-hydroxyvitamin D, BMI: body mass index, HOMA: homeostasis model assessment, LDL-c: low-density lipoprotein cholesterol, HDL-c: high-density lipoprotein cholesterol, VLDL-c: very low-density lipoprotein cholesterol, LDL: low-density lipoprotein, NEFA: non-esterified fatty acids, ApoB: apolipoprotein B, CRP: C-reactive protein.